Skip to content

SLSN SLSN Additional Paid-In Capital

Additional Paid-In Capital at other companies

Ashland logo
AshlandASH
$6M
The Beauty Health Company logo
The Beauty Health CompanySKIN
$581.05M+2.0%
NuSkin Enterprises logo
NuSkin EnterprisesNUS
$613.89M-1.5%
Colgate-Palmolive logo
Colgate-PalmoliveCL
$4.39B+4.5%
Future Fuel logo
Future FuelFF
$203.65M-1.0%
e.l.f. Beauty logo
e.l.f. BeautyELF
$1.28B+36.4%

Other financials

Income statement

See full
Revenue$13.0M-11.4%
Gross profit$3.3M-1.3%
Operating income-$504.0K-297%
Net income-$766.0K-1,058%
EPS (diluted)-$0.01

Balance sheet

See full
Cash & equivalents$573.0K-68.5%
Total debt$9.7M-3.3%
Total equity$17.0M+11.9%
Total assets$47.8M-16.2%

Cash flow

See full
Operating cash flow$1.5M+121%
CapEx$528.0K+497%
Free cash flow$989.0K+113%

Valuation

See full
Market cap$51.91M-85.0%
Enterprise value$61.08M-82.5%
P/E55×
P/S0.9×-4.5×

Profitability

See full
Gross margin26.5%-1.5pp
Operating margin1.3%-6.5pp
Net margin1.6%
FCF margin-20.1%

Returns & leverage

See full
Return on equity5.9%
Debt / equity0.6×-0.1×
Current ratio2.1×+1.0×

Where this comes from

Reported directly by SLSN in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: SLSN’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SLSN's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SLSN's additional paid-in capital?
SLSN (SLSN) reported additional paid-in capital of $115.67M in Q1 2026.
How has SLSN's additional paid-in capital changed year-over-year?
SLSN's additional paid-in capital increased by 0.7% year-over-year, from $114.8M to $115.67M.
What is the long-term trend for SLSN's additional paid-in capital?
Over 5 years (2020 to 2025), SLSN's additional paid-in capital has grown at a 2.5% compound annual growth rate (CAGR), from $102.12M to $115.57M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.